Screening serine/threonine and tyrosine kinase inhibitors for histidine kinase inhibition

Abstract

Histidine kinases of bacterial two-component systems are promising antibacterial targets. Despite their varied, numerous roles, enzymes in the histidine kinase superfamily share a catalytic core that may be exploited to inhibit multiple histidine kinases simultaneously. Characterized by the Bergerat fold, the features of the histidine kinase ATP-binding domain are not found in serine/threonine and tyrosine kinases. However, because each kinase family binds the same ATP substrate, we sought to determine if published serine/threonine and tyrosine kinase inhibitors contained scaffolds that would also inhibit histidine kinases. Using select assays, 222 inhibitors from the Roche Published Kinase Set were screened for binding, deactivation, and aggregation of histidine kinases. Not only do the results of our screen support the distinctions between ATP-binding domains of different kinase families, but the lead molecule identified also presents inspiration for further histidine kinase inhibitor development.

Strategies to attenuate the competence regulon in Streptococcus pneumoniae

“…With the peptide approach, altering the peptide scaffold to construct pharmacologically enhanced peptidomimetic scaffolds could offer a viable pathway to make these lead compounds more druggable. Alternatively, diverging completely from the peptidic scaffolds into small molecule-based scaffolds that still interact with the target histidine kinase receptor, as was successfully implemented in several other systems, [90][91][92][93] may prove to be the way to convert these anti-virulence compounds into drug leads.…”

Inhibiting DosRST As a New Approach to Tuberculosis Therapy

“…Targeting TCS has been an active area of research to translate studies of bacterial pathogenesis into new classes of antivirulence antibiotics [9,10,72]. A variety of approaches have been employed to discover TCS inhibitors, including whole cell reporter-based high-throughput screens (HTS) [45,64,65,73]; phenotypic HTS targeting TCSdependent responses [74]; target-based biochemical assays focused on inhibition of bacterial histidine kinase activity by small molecules [75][76][77] or response regulator mimetic peptides [78,79]; or inhibition of response regulator DNA binding [80,81]. These approaches have generated several new compounds that are in preclinical development as novel antivirulence therapies.…”

Modified nucleoside triphosphates in bacterial research for in vitro and live-cell applications

“…Fluorescence based-assays are commonly implemented for the high-throughput screening (HTS) of compounds against bacterial targets. 156,157 For instance, Bhat et al put to use g-AmNS-UTP in a HTS to assess the potency of 670 000 compounds against RNAP from E. coli as a mimic of RNAP from M. tuberculosis due to safety considerations. The hits were validated via a complementary radioactive assay using View Article Online mycobacterial RNAP, with a 20% rate of false positives, possibly explained by the fact that the RNAP from E. coli was used instead of that from Mycobacteria in the initial HTS.…”